

Hakim Djaballah

Founder, President and CEO, Keren Therapeutics
TPAC Chair | TPAC member since 2017

Dr. Hakim Djaballah obtained his B.S. with honours in biochemistry and biotechnology from the University of Birmingham and completed his Ph.D. in biochemistry from the University of Leicester, both in England. He began his professional career at the RW Johnson Pharmaceutical Research Institute, a Johnson & Johnson company, in La Jolla, USA followed by positions of increasing responsibilities at various pharma and biotech companies. In 2003, he was recruited to the Memorial Sloan Kettering Cancer Center in New York, USA; where he was a Research Professor and Director of the high throughput screening core, an applied research laboratory dedicated to dissecting cancer biology through functional genomics leading to the discovery and development of novel cancer therapeutics. In 2014, he was appointed CEO and director of the Institut Pasteur in Seoul, South Korea, a translational research institute focusing on infectious diseases and oncology; and joined faculty at the University of Science and Technology as Professor of Chemical Biology in Daejeon, South Korea. In 2016, he co-founded Keren Therapeutics, a clinical stage startup company dedicated to age-related cognitive declines. To date, he has published more than 100 articles. He is an inventor on a number of patents and a founder of four biotech companies. He is the recipient of the 2007 Robots and Vision User Recognition Award.